{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:03:55Z","timestamp":1790870635133,"version":"4.1.0"},"reference-count":80,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"abstract":"\n Importance<\/jats:title>\n Despite the integration of bevacizumab and poly(ADP-ribose) polymerase inhibitors into first-line treatment of advanced high-grade serous ovarian cancer, survival remains poor for the substantial subset of patients whose tumors respond insufficiently to platinum-based chemotherapy and who, therefore, frequently do not achieve complete cytoreductive surgery (the 2 red flags population). This Review examines the rationale, current evidence, and emerging strategies for systemic treatment intensification\u2014or chemosensitization\u2014aimed at improving tumor response before initiating maintenance therapy.<\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n \n Achieving minimal residual disease before maintenance depends on 2 key determinants: surgical completeness and intrinsic tumor chemosensitivity. Pragmatic indicators of chemosensitivity\u2014KELIM (modeled cancer antigen 125 elimination rate constant K), pathological chemotherapy response score, and radiologic response\u2014are now cited in European Society for Medical Oncology\u2013European Society of Gynaecological Oncology and American Society of Clinical Oncology guidelines, while\n BRCA<\/jats:italic>\n \/homologous recombination deficiency status may not reliably predict neoadjuvant carboplatin-paclitaxel response. Across post hoc analyses of phase 3 trials (ICON-7, GOG-0218, ICON-8, ICON-8B, VELIA, and IMagyn050), patients with poorly chemosensitive disease may have derived greater benefit from intensification strategies. Weekly dose-dense paclitaxel was associated with improved survival in the 2 red flags subgroup of ICON-8. Bevacizumab, added either to standard postoperative chemotherapy or to neoadjuvant dose-dense chemotherapy, showed signals of greater benefit on both progression-free and overall survival in high-risk and poorly chemosensitive subsets. In contrast, poly(ADP-ribose) polymerase inhibitor and immune checkpoint inhibitor combinations showed meaningful activity only in selected subgroups, supporting further evaluation of innovative DNA repair\u2013targeting agents and immunotherapeutic approaches in these populations.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Early identification of poorly chemosensitive advanced high-grade serous ovarian cancer enables a response-adapted first-line strategy in which treatment intensification is selectively offered to patients most likely to benefit\u2014an approach now being prospectively evaluated in the phase 3 SALVOVAR and phase 1\/2 RegeNovar trials. This framework provides a clinically actionable platform to test novel therapies aimed at increasing complete interval cytoreduction rates and improving survival in a population with otherwise limited options.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.3875","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:45:00Z","timestamp":1790869500000},"source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer"],"prefix":"10.1001","author":[{"given":"Benoit","family":"You","sequence":"first","affiliation":[{"name":"Medical Oncology, Lyon University Hospital, EPSILyon, Lyon, France"},{"name":"CICLY, Claude Bernard University Lyon 1, University of Lyon, Lyon, France"},{"name":"GINECO, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clamp","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center at Nebraska Medicine, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Bruchim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Technion Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Corbaux","sequence":"additional","affiliation":[{"name":"CICLY, Claude Bernard University Lyon 1, University of Lyon, Lyon, France"},{"name":"GINECO, Paris, France"},{"name":"Medical Oncology, Saint-Etienne University Hospital (CHUSE), Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Woong","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"del Pilar Estevez-Diz","sequence":"additional","affiliation":[{"name":"Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[{"name":"Medical Oncology, Lyon University Hospital, EPSILyon, Lyon, France"},{"name":"CICLY, Claude Bernard University Lyon 1, University of Lyon, Lyon, France"},{"name":"GINECO, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind M.","family":"Glasspool","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde and School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Program in Solid Tumors, Cima Universidad de Navarra, Cancer Center Clinica Universidad de Navarra, Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[{"name":"Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Gynecologic Oncology, Evang Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[{"name":"GINECO, Paris, France"},{"name":"Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[{"name":"Center for Gynecologic Cancer, National Cancer Center, Goyang, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"},{"name":"IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Gynecological Oncology Medical Unit, Humanitas San Pio X, Milan, Italy"},{"name":"Gynecologic Oncology Unit, Department of Woman\u2019s and Child Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"},{"name":"Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[{"name":"Gynecological Oncology Medical Unit, Humanitas San Pio X, Milan, Italy"},{"name":"Gynecologic Oncology Unit, Department of Woman\u2019s and Child Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"},{"name":"Catholic University of the Sacred Heart, Rome, Italy"},{"name":"Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[{"name":"Late-Phase Clinical Research, Florida Cancer Specialists and Research Institute, University of Central Florida College of Medicine, West Palm Beach"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Morgan","sequence":"additional","affiliation":[{"name":"The University of Manchester and Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asima","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"Kolkata Gynaecological Oncology Trials and Translational Research Group (KolGoTrg), Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Olawaiye","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella Maria","family":"Parma","sequence":"additional","affiliation":[{"name":"Istituto Europeo di Oncologia, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Edy","family":"Pierre","sequence":"additional","affiliation":[{"name":"Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Yu","family":"Tse","sequence":"additional","affiliation":[{"name":"Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Yanaihara","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[{"name":"GINECO, Paris, France"},{"name":"Centre L\u00e9on Berard, Claude Bernard University Lyon I, University of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"5","key":"crv260004r1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer.","volume":"21","author":"Webb","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"crv260004r2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"crv260004r3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer.","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"crv260004r4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(22)00283-2","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.","volume":"23","author":"Clamp","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"crv260004r5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"crv260004r6","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv260004r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102893","article-title":"ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis.","volume":"36","author":"Clamp","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"34","key":"crv260004r8","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45).","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"crv260004r9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial.","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"crv260004r10","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-024-03003-9","article-title":"Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.","volume":"30","author":"Wu","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"crv260004r11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial.","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"crv260004r12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial.","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"crv260004r13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial.","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"crv260004r14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update.","volume":"43","author":"Gaillard","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv260004r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.106032","article-title":"ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer.","volume":"11","author":"Gonz\u00e1lez-Mart\u00edn","year":"2026","journal-title":"ESMO Open"},{"key":"crv260004r16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5500","article-title":"TRUST: Trial of Radical Upfront Surgical Therapy in Advanced Ovarian Cancer (ENGOT ov33\/AGO-OVAR OP7).","volume":"43","author":"Mahner","year":"2025","journal-title":"J Clin Oncol"},{"key":"crv260004r17","doi-asserted-by":"publisher","first-page":"A575","DOI":"10.1136\/ijgc-2024-ESGO.1120","article-title":"#1072 Assessment of the prognostic impact of the European Society of Gynecologic Oncology quality indicators for advanced ovarian cancer surgery.","volume":"34","author":"Concin","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"crv260004r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.39893","article-title":"Utilization of primary cytoreductive surgery for advanced-stage ovarian cancer.","volume":"7","author":"Bercow","year":"2024","journal-title":"JAMA Netw Open"},{"key":"crv260004r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102945","article-title":"Optimal bevacizumab treatment strategy in advanced ovarian cancer: a review.","volume":"137","author":"Monk","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"crv260004r20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial.","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"30","key":"crv260004r21","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial.","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv260004r22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"crv260004r23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JCO.22.00430","article-title":"CA-125 KELIM as a potential complementary tool for predicting veliparib benefit: an exploratory analysis from the VELIA\/GOG-3005 study.","volume":"41","author":"You","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"crv260004r24","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol"},{"issue":"16","key":"crv260004r25","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1200\/JCO.2023.41.16_suppl.5591","article-title":"The role of Chemotherapy Response Score (CRS) in the decision making process for patients with advanced high grade serous ovarian cancer undergoing neoadjuvant chemotherapy.","volume":"41","author":"Marchetti","year":"2023","journal-title":"J Clin Oncol"},{"key":"crv260004r26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ygyno.2025.02.016","article-title":"Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.","volume":"195","author":"Marchetti","year":"2025","journal-title":"Gynecol Oncol"},{"key":"crv260004r27","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.22.00188","article-title":"Benefit from fractionated dose-dense chemotherapy in patients with poor prognostic ovarian cancer: ICON-8 trial.","volume":"7","author":"Colomban","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"key":"crv260004r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112966","article-title":"Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: a Gynaecologic Cancer Intergroup meta-analysis.","volume":"191","author":"Corbaux","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"crv260004r29","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e34","article-title":"Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a \u201creal-life setting\u201d.","volume":"35","author":"van Wagensveld","year":"2024","journal-title":"J Gynecol Oncol"},{"issue":"17","key":"crv260004r30","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination Rate Constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial.","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"key":"crv260004r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102294","article-title":"The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.","volume":"100","author":"You","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"crv260004r32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1136\/ijgc-2023-004872","article-title":"Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.","volume":"34","author":"Bouvarel","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"crv260004r33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/ijgc-2020-001248","article-title":"Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update.","volume":"30","author":"Fotopoulou","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"47","key":"crv260004r34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040487","article-title":"Predictive impact of clinical factors on chemosensitivity in advanced high-grade serous ovarian carcinoma according to chemotherapy response score.","volume":"103","author":"Park","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"crv260004r35","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41416-024-02874-6","article-title":"Germline BRCA1\/2 status and chemotherapy response score in high-grade serous ovarian cancer.","volume":"131","author":"Morgan","year":"2024","journal-title":"Br J Cancer"},{"key":"crv260004r36","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00469","article-title":"Predictors of successful neoadjuvant chemotherapy and interval cytoreductive surgery in management of ovarian cancer.","author":"Marchetti","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"crv260004r37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","article-title":"Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.","volume":"22","author":"Morgan","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1125","key":"crv260004r38","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210117","article-title":"The role of CT, PET-CT, and MRI in ovarian cancer.","volume":"94","author":"Engbersen","year":"2021","journal-title":"Br J Radiol"},{"issue":"9","key":"crv260004r39","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1007\/s00259-023-06235-y","article-title":"A comparative study of [68Ga]Ga-FAPI-04 PET\/MR and [18F]FDG PET\/CT in the diagnostic accuracy and resectability prediction of ovarian cancer.","volume":"50","author":"Xi","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"crv260004r40","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1038\/s41467-023-41820-7","article-title":"Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer.","volume":"14","author":"Crispin-Ortuzar","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"crv260004r41","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1136\/ijgc-2024-005313","article-title":"Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis.","volume":"34","author":"Taliento","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"8090","key":"crv260004r42","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41586-025-09580-0","article-title":"Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA.","volume":"647","author":"Williams","year":"2025","journal-title":"Nature"},{"key":"crv260004r43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ygyno.2024.12.004","article-title":"Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer: an ancillary analysis of the CHIVA phase II GINECO trial.","volume":"192","author":"Aza\u00efs","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"1","key":"crv260004r44","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ygyno.2020.07.021","article-title":"Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).","volume":"159","author":"Robelin","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"1","key":"crv260004r45","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41698-025-01080-8","article-title":"Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer.","volume":"9","author":"Koedoot","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"crv260004r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102892","article-title":"Impact of KELIM chemosensitivity and interval cytoreduction on survival outcomes from neoadjuvant weekly dose-dense paclitaxel +\/- bevacizumab: pooled analysis of ICON8 and ICON8B phase III trials.","volume":"36","author":"You","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"crv260004r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.108156","article-title":"109RO Continuous relationship between KELIM chemosensitivity and survival benefit from chemotherapy intensification (standard or dose-dense; with\/without bevacizumab): ICON8 & 8B.","volume":"11","author":"You","year":"2026","journal-title":"ESMO Open"},{"issue":"26","key":"crv260004r48","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer.","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"crv260004r49","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa026","article-title":"Bevacizumab for newly diagnosed ovarian cancers: best candidates among high-risk disease patients (ICON-7).","volume":"4","author":"Colomban","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"34","key":"crv260004r50","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study.","volume":"40","author":"You","year":"2022","journal-title":"J Clin Oncol"},{"key":"crv260004r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115587","article-title":"Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: final overall survival and disease-related symptoms results.","volume":"225","author":"Coleman","year":"2025","journal-title":"Eur J Cancer"},{"issue":"17","key":"crv260004r52","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39).","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"crv260004r53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ygyno.2025.04.577","article-title":"Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: a retrospective analysis from the IMagyn050 trial.","volume":"197","author":"You","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"1","key":"crv260004r54","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/s41467-024-46999-x","article-title":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.","volume":"15","author":"Ray-Coquard","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"crv260004r55","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1038\/s41467-024-47000-5","article-title":"Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.","volume":"15","author":"Le Saux","year":"2024","journal-title":"Nat Commun"},{"issue":"13","key":"crv260004r56","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial.","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"crv260004r57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","article-title":"Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial.","volume":"70","author":"Rouzier","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"crv260004r58","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/1078-0432.CCR-23-0771","article-title":"Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T\/MINOVA study).","volume":"30","author":"Tavira","year":"2024","journal-title":"Clin Cancer Res"},{"key":"crv260004r59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e17555","article-title":"Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: a single-arm, prospective phase II trial.","volume":"42","author":"Liu","year":"2024","journal-title":"J Clin Oncol"},{"key":"crv260004r60","doi-asserted-by":"publisher","first-page":"A430","DOI":"10.1136\/ijgc-2023-ESGO.903","article-title":"The NUVOLA TRIAL: neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II open-label multi-centre study.","volume":"33","author":"Salutari","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"crv260004r61","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"key":"crv260004r62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5506","article-title":"FIRST\/ENGOT-OV44: a phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC).","volume":"43","author":"Hardy-Bessard","year":"2025","journal-title":"J Clin Oncol"},{"key":"crv260004r63","doi-asserted-by":"publisher","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","article-title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC).","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"crv260004r64","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.annonc.2025.11.020","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.","volume":"37","author":"Harter","year":"2026","journal-title":"Ann Oncol"},{"key":"crv260004r66","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105312","article-title":"Immunotherapy advancements in high-grade serous ovarian cancer: from promise to practice.","volume":"223","author":"Heidinger","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"crv260004r67","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1200\/JCO.2024.42.16_suppl.5569","article-title":"Phase Ib INEOV neoadjuvant trial of durvalumab +\/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): survival outcomes and immune correlates.","volume":"42","author":"Leary","year":"2024","journal-title":"J Clin Oncol"},{"issue":"28","key":"crv260004r68","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41388-025-03448-3","article-title":"Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.","volume":"44","author":"Narayana","year":"2025","journal-title":"Oncogene"},{"issue":"18","key":"crv260004r69","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.3390\/ijms251810018","article-title":"Enhancing therapeutic response and overcoming resistance to checkpoint inhibitors in ovarian cancer through cell cycle regulation.","volume":"25","author":"Wang","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"497","key":"crv260004r70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7534","article-title":"A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.","volume":"11","author":"Crawford","year":"2019","journal-title":"Sci Transl Med"},{"key":"crv260004r71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1302307","article-title":"CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer.","volume":"14","author":"Nasiri","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"crv260004r72","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"crv260004r73","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/ijc.34124","article-title":"Effect of HIPEC according to HRD\/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial.","volume":"151","author":"Koole","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"crv260004r74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102746","article-title":"Utility of CA125 KELIM in predicting benefit from hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer: pooled analysis of KGOG3042 and KOV-HIPEC-01.","volume":"36","author":"Cho","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"crv260004r76","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251396777","article-title":"SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.","volume":"17","author":"Chator","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"13","key":"crv260004r79","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/S1470-2045(14)70490-5","article-title":"Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"crv260004r80","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"crv260004r65","author":"Powell","year":"2025"},{"key":"crv260004r77","author":"You","year":"2026"},{"key":"crv260004r75","unstructured":"Utility of adjusting chemotherapy dose & dosing schedule with the salvage weekly dose-dense regimen in patients with poor prognostic ovarian cancers based on the tumor unfavorable primary chemosensitivity and incomplete debulking surgery (SALVOVAR). ClinicalTrials.gov identifier: NCT06476184. Accessed September 16, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06476184"},{"key":"crv260004r78","unstructured":"Safety and efficacy of ubamatamab with first-line chemotherapy in ovarian cancer (RegeNovar). ClinicalTrials.gov identifier: NCT07637851. Accessed September 16, 2026. https:\/\/clinicaltrials.gov\/study\/NCT07637851"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2854857\/jamaoncology_you_2026_rv_260004_1790631727.9948.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:45:02Z","timestamp":1790869502000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2854857"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":80,"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.3875","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}